AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
ADMA Biologics, Inc.
Video analysis: ADMA
All videosNo video analysis for this stock yet. Request one from our team.
News: ADMA
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company").
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PR Newswire
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
